Physician profile
John Dent
NPI 1457989634
$1,327.27
in general payments reported to CMS, 2019-2025
14 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $147 · 2023: $322 · 2024: $615 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $361.41 | 2024-2025 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
| Astrazeneca Pharmaceuticals Lp | $205.39 | 2023-2024 | Fasenra, Tezspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $146.72 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $145.93 | 2023-2024 | Opsumit |
| Melinta Therapeutics, LLC | $125.00 | 2023 | Rezzayo |
| Insmed, INC. | $76.38 | 2023-2024 | Arikayce |
| Merck Sharp & Dohme LLC | $49.24 | 2024-2025 | Zerbaxa, Winrevair |
| Janssen Pharmaceuticals, INC | $43.70 | 2023-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $42.62 | 2024 | Takhzyro, Glassia |
| Regeneron Healthcare Solutions, INC. | $39.36 | 2024 | Dupixent |
| Genentech USA, INC. | $37.48 | 2024 | Xolair, Alecensa, Tecentriq |
| Verona Pharma, INC. | $21.26 | 2025 | Ohtuvayre |
| Haemonetics Corporation | $19.41 | 2024 | Teg5000 Hemostasis Analyzer |
| Glaxosmithkline, LLC. | $13.37 | 2024 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.